Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary collaboration to co-develop and market the product in 2Q17, which became a definitive agreement later in the year.
Three Phase III studies are underway with the HA/NSAID formulation, including:
- This confirmatory study in the knee
- A study of OA in the shoulder, elbow, hip and ankle
- A long-term study in OA patients to evaluate safety
This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 440 patients with knee OA. ONO-5704/SI-613 demonstrated a statistically significant improvement in knee pain scores vs. placebo at 12 weeks after the initial injection, with no major safety concerns observed in the ONO-5704/SI-613 group. Ono and Seikagaku plan to file for manufacturing and marketing approval in 1H20, after evaluation of data from all three studies.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary...
Seikagaku and Ono Pharmaceutical obtained positive topline results from a Phase III confirmatory study of ONO-5704/SI-613 in the treatment of knee osteoarthritis (OA).
ONO-5704/SI-613 is a combination of hyaluronic acid (HA) and an NSAID to address pain and inflammation through a 3-injection regimen. Ono and Seikagaku formed a preliminary collaboration to co-develop and market the product in 2Q17, which became a definitive agreement later in the year.
Three Phase III studies are underway with the HA/NSAID formulation, including:
- This confirmatory study in the knee
- A study of OA in the shoulder, elbow, hip and ankle
- A long-term study in OA patients to evaluate safety
This randomized, double-blind, placebo-controlled, parallel-group comparative study involved 440 patients with knee OA. ONO-5704/SI-613 demonstrated a statistically significant improvement in knee pain scores vs. placebo at 12 weeks after the initial injection, with no major safety concerns observed in the ONO-5704/SI-613 group. Ono and Seikagaku plan to file for manufacturing and marketing approval in 1H20, after evaluation of data from all three studies.
Sources: Seikagaku Corporation; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.